EDWARDS LIFESCIENCES CORPORATION |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 88.01 USD | -0.68% |
|
+1.80% | +15.42% |
| 12:21am | Edwards Lifesciences first-quarter profit beats estimates on heart devices strength | RE |
| Apr. 25 | Transcript : Edwards Lifesciences Corporation, Q1 2024 Earnings Call, Apr 25, 2024 |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
Edwards Lifesciences Corporation specializes in designing, manufacturing and marketing medical systems and devices for treating cardiovascular diseases. Net sales break down by family of products as follows:
- heart valves and surgery products (67.9%);
- hemodynamic monitoring systems (15.5%);
- other (16.6%): balloon catheters, artificial implants, etc.
Net sales are distributed geographically as follows: the United States (58.4%), Europe (22.2%), Japan (7.6%) and other (11.8%).
Calendar
2024-05-07
- Annual General Meeting
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
32
Last Close Price
88.01
USD
Average target price
94.48
USD
Spread / Average Target
+7.35%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +15.42% | 52.98B | |
| +7.71% | 218B | |
| +6.25% | 182B | |
| +10.60% | 132B | |
| +26.73% | 108B | |
| -0.53% | 62.51B | |
| -1.89% | 47.59B | |
| -1.91% | 39.96B | |
| +11.16% | 39.22B | |
| +6.63% | 26.94B |
- Stock Market
- Equities
- EW Stock
- News Edwards Lifesciences Corporation
- UBS Upgrades Edwards Lifesciences to Buy From Neutral, Adjusts Price Target to $126 From $121
